GF Fund Management CO. LTD. Takes Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

GF Fund Management CO. LTD. purchased a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 4,903 shares of the medical equipment provider's stock, valued at approximately $518,000.

Other institutional investors have also recently bought and sold shares of the company. Stonebridge Financial Group LLC acquired a new stake in Zimmer Biomet during the fourth quarter worth $25,000. Accredited Wealth Management LLC acquired a new stake in shares of Zimmer Biomet in the 4th quarter valued at $36,000. Kentucky Trust Co acquired a new stake in shares of Zimmer Biomet in the 4th quarter valued at $39,000. OFI Invest Asset Management acquired a new stake in shares of Zimmer Biomet in the 4th quarter valued at $40,000. Finally, Dunhill Financial LLC boosted its stake in shares of Zimmer Biomet by 86.6% in the 4th quarter. Dunhill Financial LLC now owns 444 shares of the medical equipment provider's stock valued at $47,000 after purchasing an additional 206 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on ZBH shares. Wells Fargo & Company reduced their target price on shares of Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. Stifel Nicolaus set a $115.00 target price on shares of Zimmer Biomet and gave the company a "buy" rating in a research note on Tuesday, May 6th. Robert W. Baird reduced their price target on shares of Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. Morgan Stanley reduced their price target on shares of Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. Finally, Royal Bank of Canada reduced their price target on shares of Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, Zimmer Biomet presently has an average rating of "Hold" and a consensus price target of $111.53.

Insider Buying and Selling

In other news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the transaction, the senior vice president now directly owns 8,768 shares of the company's stock, valued at $915,379.20. This trade represents a 14.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.70% of the stock is owned by company insiders.

Zimmer Biomet Stock Down 0.9%

NYSE ZBH traded down $0.87 during trading hours on Friday, reaching $92.47. 541,724 shares of the company's stock were exchanged, compared to its average volume of 1,793,074. The company's 50-day moving average is $100.36 and its two-hundred day moving average is $104.92. Zimmer Biomet Holdings, Inc. has a one year low of $89.92 and a one year high of $116.71. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. The company has a market capitalization of $18.30 billion, a price-to-earnings ratio of 20.80, a price-to-earnings-growth ratio of 1.95 and a beta of 0.78.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. The business had revenue of $1.91 billion during the quarter, compared to analysts' expectations of $1.89 billion. During the same period in the prior year, the business earned $1.94 EPS. Zimmer Biomet's revenue for the quarter was up 1.1% compared to the same quarter last year. On average, analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Thursday, June 26th will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 1.04%. Zimmer Biomet's payout ratio is 21.24%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.